| 2.89 -0.15 (-4.93%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.35  |
1-year : | 4.97 |
| Resists | First : | 3.72 |
Second : | 4.26 |
| Pivot price | 3.44 |
|||
| Supports | First : | 2.86 |
Second : | 2.38 |
| MAs | MA(5) : | 3.05 |
MA(20) : | 3.56 |
| MA(100) : | 4.13 |
MA(250) : | 3.51  |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 4.5 |
D(3) : | 4.2 |
| RSI | RSI(14): 21.9 |
|||
| 52-week | High : | 5.49 | Low : | 1.97 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ WHWK ] has closed above bottom band by 4.8%. Bollinger Bands are 37.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.04 - 3.06 | 3.06 - 3.07 |
| Low: | 2.82 - 2.84 | 2.84 - 2.86 |
| Close: | 2.86 - 2.89 | 2.89 - 2.92 |
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Thu, 08 Oct 2026
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Stock Has Consensus Target Price of $8.33 According to Brokerages - MarketBeat
Thu, 01 Oct 2026
Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026 - PR Newswire
Sat, 26 Sep 2026
Insiders At Whitehawk Therapeutics Sold US$2.5m In Stock, Alluding To Potential Weakness - Simply Wall Street
Sun, 13 Sep 2026
A lung cancer target stayed largely stable after treatment. Whitehawk is testing a targeted drug. - Stock Titan
Thu, 10 Sep 2026
Five brands, more than 20 countries. Whitehawk adds an oncology leader to its board. - Stock Titan
Fri, 28 Aug 2026
What Makes Whitehawk Therapeutics, Inc. (WHWK) a Strong Momentum Stock: Buy Now? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 57 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 12.6 (%) |
| Held by Institutions | 81 (%) |
| Shares Short | 2,710 (K) |
| Shares Short P.Month | 2,980 (K) |
| EPS | -1.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.46 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.8 % |
| Return on Equity (ttm) | -45 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.51 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -69 (M) |
| Levered Free Cash Flow | -44 (M) |
| PE Ratio | -2.52 |
| PEG Ratio | 0 |
| Price to Book value | 1.17 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|